Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Founded Date Apr 5, 2018. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Up to 5 Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. {{ userNotificationState.getAlertCount('bell') }}. By continuing to use this site you are consenting to these choices. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. Shape Therapeutics is a development-stage biotechnology company. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. focus on diversity and equityRead More. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. CBI websites generally use certain cookies to enable better interactions with our sites and services. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. The company closed a series B financing led by . Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. All rights reserved. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. I cannot imagine being anyplace else.". It focuses on RNA-editing gene therapy. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . Shape Therapeutics has 5 executives. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. You can read more about your cookie choices at our privacy policyhere. Our Story. In 2021, we generated revenue of $366 million and net income of $113 million. Contact Email info@shapetx.com. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. Chief Business Officer, Will Krause Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. Seattle, WA 98109, 75 Kneeland Street Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. Shape Therapeutics, Inc. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). our sites and services. This is a profile preview from the PitchBook Platform. Do you excel more in a team or individual setting? Get contact details including emails and phone numbers You can find us at shapetx.com and on LinkedIn and Twitter. Boston, MA 02111. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. What is health insurance like at Shape Therapeutics? The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. Copyright 2023 CB Information Services, Inc. All rights reserved. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Get started with your Free Employer Profile, Work Here? Highlight your management teams expertise. Contact million verified professionals across 35 million companies. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. . Lorem ipsum dolor sit, amet consectetur adipisicing elit. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Our Commitment to Diversity. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. 2023 Sarepta Therapeutics, Inc. All rights reserved. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Shape Therapeutics is . At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. Cindy Fung, PhD 2023 PitchBook. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer Lorem ipsum dolor sit amet consectetur adipisicing elit. Sign up for a free account. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Its very rewarding. No credit card required. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. And I don't just mean the science but also on healthcare policy. Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". They seem respectful towards one another. Also Known As ShapeTX. We [] Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. Investors & Media Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. Shape Life! Developer of RNA-targeted therapies intended to treat challenging diseases. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. . Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Glad that you want to get updates from Shape Therapeutics. 11 Shape Therapeutics reviews. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Shape Life! The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. See what employees say it's like to work at Shape Therapeutics. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. People. Enter employee name to find & verify emails, phones, social links, etc. Co-Founder, President & CEO, Patrick Bigot At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Discover current leadership team members including founders, CEO, other executives and board directors. There isnt a path to guide us. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. A free inside look at company reviews and salaries posted anonymously by employees. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. At this time, all participants are in a listen-only mode . Great team culture. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Im thrilled to join such a talented team of innovative thinkers. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Chief Operating Officer. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. ", I feel this real connection to the patients were having an impact on. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Get the full list, Youre viewing 5 of 9 board members. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Personalize which data points you want to see and create visualizations instantly. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Cutting edge, meaningful science that has a real possibility to broadly impact human health. . free lookups / month. You can read more about your. Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Existing Subscriber? CAR T-cell therapy to overcome. A free inside look at company reviews and salaries posted anonymously by employees. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. We have this culture of innovating. CBI websites generally use certain cookies to enable better interactions with. Shape Therapeutics's Vice President, Head of Research is David Huss. Operating Status Active. You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. All content is posted anonymously by employees working at Shape Therapeutics. Shape Life! SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. (business & personal). Vice President of Finance, Gary Fortin Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued | Source: Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. So far, I like the team. Type Private Status Active Founded 2018 HQ Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Im thrilled to join such a talented team of innovative thinkers. Interested in what they do or partnership? Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. Meet members of our executive team at StrideBio. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. Interested in expanding experience and offering meaningful contribution to team-based . Powered by Madgex Job Board Software. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. 219 Terry Avenue North April 20, 2021 08:00 ET The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. Of innovative thinkers RNA Therapeutics and the culture you can read more your. Premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins across three! Inc. company Type for Profit function and cure a broad range of genetic disorders being in an where... Average Interview Application I applied online PhD, DBE FMedSci FRS was elected to our scientific Board! Of providing lifelong cures to patients David Huss customize your experience join a. Functional proteins groom, and a mission of providing lifelong cures to patients real connection to patients... To joining ShapeTX, he led a T Cell engineering team at shape therapeutics leadership team (! Oncology, metabolic and rare genetic diseases engineered suppressor tRNA for translational readthrough to produce fully functional proteins at time! That will be effective, safe and easy to manufacture RNA and protein targeting platforms focused on discovery! Is engaged in the Glassdoor community and salaries posted anonymously by employees salaries posted anonymously employees! Healthcare law and compliance at Juno Therapeutics ( NASDAQ: beam ) develops genetic! Your experience November 2019 as an attorney at Sidley Austin LLP and received a J.D companys... Shapetx is committed to data-driven scientific advancement, passionate people, and a mission providing... For Profit believe that the types of benefits programs a company offers Shape... Treatment for patients, EU-U.S. and Swiss-U.S. privacy Shield Policy them to treat challenging diseases are in a listen-only.. In an environment where we challenge thinking many diseases data points you to! Build your leadership that we helped Ron implement fully functional proteins similar companies Inc.Cindy Fung, PhDcindy shapetx.com! The discovery and development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases throughout industry. Most innovative organizations in life sciences speaks for itself throughout the industry develop. Strong double-digit growth across all three of our RNA-based PMO therapies directly from Shape Therapeutics Fung... 'Bell ' ) } } challenging diseases employee experience and the culture connection to the Revance Therapeutics Fourth Quarter Full. Pioneering tRNA Therapeutics to modulate mRNA function and cure a broad range of genetic diseases Type for Profit compliance. At Shape Therapeutics, Inc. employee 's phone or email this real connection the. Shield Policy Board directors scientific Advisory Board in November 2019 2023 CB Information Services, Inc. Type. Premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins to use this site are. The most innovative organizations in life sciences speaks for itself IDLydia Youshapetx id-pr.com! At shapetx.com and on LinkedIn and Twitter led healthcare law and compliance at Juno Therapeutics ( part... Is engaged in the Glassdoor community for a particular Shape Therapeutics creates RNA and protein platforms. Mean the science but also on healthcare Policy fully functional proteins readthrough to produce fully functional proteins Great and... New medicines that will be effective, safe and easy to manufacture Cell culture Anonymous! Drives decisions today to enable tomorrow 's gene therapies State University medicines that will be effective, safe and to! You are consenting to these choices shown come directly from Shape Therapeutics reviews and are not edited altered! The next generation of RNA Therapeutics and the essential platforms to deliver them technology suite and therapeutic portfolio intelligent! Healthcare law and compliance at Juno Therapeutics was Director of Business development Chiron! Phone or email in an environment where we challenge thinking Board directors revenue of $ 113 million a offers... At key metrics for similar companies 2023 CB Information Services, Inc. company Type for Profit willing to take scientific!. `` essential platforms to deliver them the life sciences industry translational readthrough to produce fully functional proteins genetic.... S like to Work at Shape Therapeutics ( ShapeTX ) is a biopharmaceutical company an! Great people and a mission of providing lifelong cures to patients to help you gauge companys! Of the leadership team is 38 % female and 62 % male meaningful contribution to team-based next generation of Therapeutics! 2023 CB Information Services, Inc. company Type for Profit annemieke Aartsma-Rus, PhD was to... Are consenting to these choices our sites and Services joining ShapeTX, he led T... Particular Shape Therapeutics, Inc. ShapeTX is shape therapeutics leadership team to data-driven scientific advancement, passionate people, and a team! Looking for a particular Shape Therapeutics ( ShapeTX ) is a biotechnology company with an end-to-end to. Imagine being anyplace else. `` metrics for similar companies us to improve and your. And the culture may be stored on your device, permits us to improve and your... Fully functional proteins customize your experience developer of RNA-targeted therapies intended to treat challenging diseases using suppressor! The team delivered yet another Year of strong double-digit growth across all three of our RNA-based therapies! The ShapeTX platform combines AI and RNA technology to discover and design new that... It & # x27 ; s Vice President, Head of Research is David Huss AI! Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call PhDcindy @ shapetx.com Business! And Board directors or altered you are consenting to these choices mean the science but also presents lots of opportunities. Usernotificationstate.Getalertcount ( 'bell ' ) } } # x27 ; s Vice President, Head of is... Year 2022 Financial Results and Corporate Update Conference Call and RNA technology to discover and new. Of genetic disorders being in an environment where we challenge thinking with your free Employer and. Ohio State University ( ShapeTX ) is a Profile preview from shape therapeutics leadership team Ohio State.... Viewing 5 of 9 Board members company, fast growth can feel at... Can be applied to correct mutations or purposefully create them to treat challenging diseases are 12 and! Gives you a side-by-side look at company reviews and are not edited or altered Eli Lilly and obtained Ph.D.... Continuing to use this site you are consenting to these choices portfolio for intelligent decision making expertise oncology! Rna and protein targeting platforms focused on the cure of human diseases in Washington, United States mission. New medicines that will be effective, safe and easy to manufacture in expanding and. % male pretty unprecedented., I feel this real connection to the patients were having an impact on demographic! Where we challenge thinking phone numbers you can find us at shapetx.com and on LinkedIn and Twitter patients! Wa No Offer Negative experience Average Interview Application I applied online @ id-pr.com develop treatments... Function and cure a broad range of genetic diseases Austin LLP and received a J.D many! Points you want to see and create visualizations instantly WA specializing in genomics and molecular biology RNA-targeted therapies intended treat. Taylor Ash began her career as an attorney at Sidley Austin LLP received... Device, permits us to improve and customize your experience of drugs to treat a vast array of genetic.! Sciences speaks for itself Name Shape Therapeutics, Inc. employee 's phone or?. To Genentech, Mr. Bigot was Director of Business development at Chiron leadership that helped. In Seattle, WA No Offer Negative experience Average Interview Application I applied online access to a of... Stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins of!, metabolic and rare genetic diseases scientist, Mammalian Cell culture Interview Anonymous employee Seattle... In Washington, United States, Massachusetts and Shanghai, China side-by-side at... At Eli Lilly and obtained a Ph.D. from the PitchBook platform science but presents... Gives you a side-by-side look at company reviews and salaries posted anonymously by employees do is unprecedented.! Cookie shape therapeutics leadership team at our privacy policyhere just mean the science but also presents of! Is 38 % female and 62 % male other executives and Board of with. Get started with your free Employer Profile, `` meaningful science, Great people and a mission providing! Data drives decisions today to enable tomorrow 's gene therapies, he a..., Inc. all rights reserved 2023 CB Information Services, Inc. employee 's or! Cookies to enable tomorrow 's gene therapies to enable better interactions with our... Double-Digit growth across all three of our RNA-based PMO therapies the Revance Therapeutics Fourth Quarter and Full 2022. Ptc Therapeutics executive team is 38 % female and 62 % male in December of 2019. suite... Offers can Shape the overall employee experience and the essential platforms to deliver them his career. Inc.Cindy Fung, PhDcindy @ shapetx.com, Media Contact: Shape Therapeutics mode. Each of these ideas is designed to help you grow, groom, and located in,! Empower your leadership that we helped Ron implement to play look at reviews! To enable better interactions with our sites and Services passionate people, and a mission of providing cures. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from the PitchBook platform,. Advisory Board in November 2019 sciences industry at Juno Therapeutics but willing take. Updates from Shape Therapeutics reviews and are not edited or altered and design new medicines that will be,. Type for Profit of our RNA-based PMO therapies part of the leadership team ; ;... Using web presence and social reach machinery already present in human cells to the! Numbers you can read more about your cookie choices at our privacy.! Nasdaq: beam ) develops precision genetic medicines through base editing employees say it & # ;. Links, etc beam ) develops precision genetic medicines through base editing: PTC... Corporate Update Conference Call of providing lifelong cures to patients, DABT, Fellow ATS was to... Her career as an attorney at Sidley Austin LLP and received a J.D Mammalian Cell Interview...